Κατσιμάρδου Αλεξάνδρα

Σπουδές

• Διδάκτωρ, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (2018 - 2025)
• Πτυχίο Ιατρικής, Στρατιωτική Σχολή Αξιωματικών Σωμάτων (ΣΣΑΣ), Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (2005 - 2011)
• Πτυχίο Ιατρικής, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (2005 - 2011)
• Ειδικότητα Παθολογίας, Β' Παθολογική Κλινική, Γενικό Νοσοκομείο Θεσσαλονίκης «Ιπποκράτειο» (2017 - 2021)
• Ειδικότητα Παθολογίας, 424 Γενικό Στρατιωτικό Νοσοκομείο Εκπαιδεύσεως (2015 - 2017)
• Πιστοποίηση "Advanced Life Support (ALS)", European Resuscitation Council (ERC)

Επαγγελματική εμπειρία

• Ιδιωτικό ιατρείο, Αμπελόκηποι

Συμμετοχή σε συνέδρια

• 24ο Πανελλήνιο Συνέδριο Υπέρτασης, Ελληνική Εταιρεία Υπέρτασης, Ξενοδοχείο "Grand Hyatt Athens", Αθήνα (7 - 9/11/2024)
• 23ο Πανελλήνιο Συνέδριο Υπέρτασης, Ελληνική Εταιρεία Υπέρτασης, Ξενοδοχείο "Makedonia Palace", Θεσσαλονίκη (5 - 7/10/2023)
• 21ο Πανελλήνιο Συνέδριο, Ελληνική Εταιρεία Υπέρτασης, Ξενοδοχείο "Makedonia Palace", Θεσσαλονίκη (25 - 27/11/2021)
• 2ο Πανελλήνιο Συνέδριο Ιατρικής Εκπαίδευσης, Hellenic Society for Medical Education (HESME), Ξενοδοχείο "Valis Resort & Spa Conference Center", Βόλος (30/5 - 2/6/2019)
• 1ο Πανελλήνιο Συνέδριο Ιατρικής Εκπαίδευσης, Hellenic Society for Medical Education (HESME), Ξενοδοχείο "Valis Resort & Spa Conference Center", Βόλος (25 - 28/5/2018)
• περισσότερα

Δημοσιεύσεις

• Katsimardou A, Theofilis P, Vordoni A, et al. The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors. Int J Mol Sci. 2024 Nov; 25(22): 12384. (2024)
• Katsimardou A, Stavropoulos K, Imprialos K, et al. Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo? J Clin Hypertens (Greenwich). 2019 Oct;21(10):1578-1579 13. 617. 10.3390/metabo13050617. (2023)
• Katsimardou A, Patoulias D, Zografou I, et al. The associations between kidney function and sexual dysfunction among males and females with type 2 diabetes mellitus. Medicina 2023; 59:969. (2023)
• Katsimardou A, Patoulias D, Zografou I, et al. The impact of metabolic syndrome components on erectile function in patients with type 2 diabetes. Metabolites 2023; 13: 617. (2023)
• Patoulias D, Katsimardou A, Fragakis N, et al. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Acta Diabetol. 2023; 60: 1-8. (2023)
• Patoulias D, Katsimardou A, Imprialos K, Doumas M. Exercise, erectile dysfunction and co-morbidities: the good, the bad and the ugly. Rev Cardiovasc Med 2022; 23: 304. (2022)
• Patoulias D, Papadopoulos C, Zografou I, Katsimardou A, Karagiannis A, Doumas M. Effect of empagliflozin and dapagliflozin on ambulatory arterial stiffness in patients with type 2 diabetes mellitus and cardiovascular co-morbidities: a prospective, observational study. Medicina 2022; 58: 1167. (2022)
• Imprialos KP, Koutsampasopoulos K, Katsimardou A, et al. Female Sexual Dysfunction: A Problem Hidden in the Shadows. Curr Pharm Des. 2021;27(36):3762-377410.2174/1381612827666210719104950. (2021)
• Toumpourleka M, Patoulias D, Katsimardou A, et al. Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. Curr Pharm Des. 2021;27(10):1289-1297. (2021)
• Patoulias D, Papadopoulos C, Katsimardou A, et al. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. Am J Cardiol. 2021 Jan 15;139:134-136. (2021)
• Patoulias D, Katsimardou A, Papadopoulos C, et al. Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. Acta Diabetol. 2021 Jan;58(1):125-126. (2021)
• Faselis C, Katsimardou A, Imprialos K, et al. Microvascular Complications of Type 2 Diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):117-124. (2020)
• Katsimardou A, Imprialos K, Stavropoulos K, et al. Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev. 2020;16(1):12-18. (2020)
• Katsimardou A, Imprialos K, Stavropoulos K,et al. Treatment strategies for hypertension in patients with type 1 diabetes.Expert Opin Pharmacother. 2020 Jul;21(10):1241-1252. (2020)
• Patoulias D, Papadopoulos C, Katsimardou A, et al. Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. Am J Cardiol. 2020 Nov 1;134:149-152. (2020)
• Patoulias D, Papadopoulos C, Katsimardou A, et al. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Pol Arch Intern Med. 2020 Oct 29;130(10):922. (2020)
• Patoulias D, Katsimardou A, Stavropoulos K, et al. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Curr Hypertens Rep. 2020 Sep 10;22(11):90. (2020)
• Patoulias D, Katsimardou A, Kalogirou MS, et al. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. Diabetes Metab. 2020 Sep;46(4):272-27910.1016/j.amjcard.2020.10.001. (2020)
• Patoulias D, Katsimardou A, Kalogirou MS, et al. Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients? Dig Liver Dis. 2020 Feb;52(2):239-240. (2020)
• περισσότερα